John Hohneker
Director/Board Member bij CURIS, INC.
Vermogen: - $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
James Dentzer | M | 57 | 8 jaar | |
Hans Jörg Reinhardt | M | 68 | 40 jaar | |
Diantha Duvall | F | 52 | 2 jaar | |
Anil Singhal | M | 72 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 3 jaar |
Volker Herrmann | M | - |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | - |
Richard Morris | M | 51 | 3 jaar | |
Robert E. Martell | M | 61 | 13 jaar | |
Martyn D. Greenacre | M | 82 | 24 jaar | |
Steven Kelly | M | 59 | 6 jaar | |
Nancy Andrews | M | 65 | 9 jaar | |
Jonathan Zung | M | 59 | 3 jaar | |
Charles Sawyers | M | 65 | 11 jaar | |
Eric Siegel | M | 60 | 1 jaar | |
Scott Clarke | M | - |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 4 jaar |
Sanford Zweifach | M | 68 | 3 jaar | |
Michael Torok | M | 45 | 1 jaar | |
Briggs Morrison | M | 65 | 4 jaar | |
Marc Rubin | M | 69 | 14 jaar | |
Kenneth I. Kaitin | M | 71 | 21 jaar | |
Samir Shah | M | 63 | 20 jaar | |
Vasant Narasimhan | M | 48 | 19 jaar | |
Regina Hodits | M | 54 | 6 jaar | |
Karah Parschauer | F | 46 | 7 jaar | |
Mark W. Noel | M | 65 | 23 jaar | |
Michael Klichinsky | M | 34 | 8 jaar | |
Björn Ingemar Odlander | M | 66 | 2 jaar | |
Bill Winters | M | 62 | 11 jaar | |
Simon Brown | M | - | 11 jaar | |
Reinhard von Roemeling | M | - | 5 jaar | |
Nina Kjellson | F | 49 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 4 jaar |
Nancy Soohoo | F | - | 21 jaar | |
Dora Ferrari | F | - | 3 jaar | |
Mark D. Plinio | M | 57 | 3 jaar | |
Kimberly Steinmann | M | - | 2 jaar | |
Anthony Melendez | M | - |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 3 jaar |
Rachel Blasbalg | F | - | 20 jaar | |
Maria Petrini | F | - | 1 jaar | |
Terry Shields | F | - | 1 jaar | |
Luke Evnin | M | 60 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | - |
Scott Brun | M | 56 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | - |
Harry Werner Kirsch | M | 59 | 21 jaar | |
Charlotte Pamer-Wieser | M | - | 13 jaar | |
Leonard Dove | M | 51 | 2 jaar | |
Anne Borgman | M | 56 | - | |
David Scadden | M | 71 |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | - |
Daniel Cushing | M | - | 7 jaar | |
Shalini Sharp | F | 49 | 7 jaar | |
Linda Armstrong | M | 61 | 17 jaar | |
Shelley Chu | M | 54 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | - |
Kurt von Emster | M | 56 |
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021. | 4 jaar |
Douglas Cole | M | 63 |
Sonata Therapeutics, Inc.
Sonata Therapeutics, Inc. BiotechnologyHealth Technology Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann. | - |
Thomas Kassberg | M | 63 | 7 jaar | |
Tom Wilton | M | - | 5 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Timothy Morris | M | 61 | 6 jaar | |
William E. Steinkrauss | M | 39 | 6 jaar | |
Ronen Tamir | M | 57 | - | |
Jean Franchi | F | 57 | 2 jaar | |
Annalisa Jenkins | M | 58 | 3 jaar | |
Wendelin Wiedeking | M | 72 | 11 jaar | |
Rolf M. Zinkernagel | M | 80 | 15 jaar | |
Ann Thorell | F | 56 | 1 jaar | |
David Epstein | M | 62 | 6 jaar | |
Ulrich Lehner | M | 78 | 13 jaar | |
Joseph Jimenez | M | 64 | 11 jaar | |
Lord Darzi | M | 63 | 5 jaar | |
Christine Bellon | M | - |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 2 jaar |
Verena A. Briner | M | 72 | 3 jaar | |
Luca Scavo | M | 57 | 1 jaar | |
Eric Zhang | M | 43 | 5 jaar | |
Peter Kornicker | M | - | 20 jaar | |
Dimitri Azar | M | 65 | 7 jaar | |
Karoline Shair | M | - |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | 1 jaar |
Tonya Williams | F | 50 | 1 jaar | |
Dirk van de Put | M | 63 | 1 jaar | |
Enrico Cipro Vanni | M | 73 | - | |
Susanne Antonie Schaffert | M | 57 | 2 jaar | |
Kim Stratton | F | 62 | 3 jaar | |
Juan Andres | M | 59 | 12 jaar | |
David Perry | M | 56 | 6 jaar | |
Shannon Klinger | M | 53 | 10 jaar | |
Alexandre F. Jetzer-Chung | M | 83 | 15 jaar | |
George Migausky | M | 69 | 2 jaar | |
Theo Melas-Kyriazi | M | 64 | 6 jaar | |
Tai Ching Ho | M | 62 | 3 jaar | |
Mun Tak Yang | F | 70 | - | |
Ann Marie Fudge | F | 72 | - | |
William Brody | M | 80 | - | |
Michael Rogers | M | 64 | 4 jaar | |
Daniel Vasella | M | 70 | 17 jaar | |
Yi Li Xie | M | 54 | 2 jaar | |
Chidozie Ugwumba | M | 41 | 4 jaar | |
Srikant T. Madhav Datar | M | 70 | 18 jaar | |
Nancy Simonian | M | 63 | 3 jaar | |
Jürgen Brokatzky-Geiger | M | 72 | 14 jaar | |
Andreas von Planta | M | 68 | - | |
Lori Kunkel | M | 66 | 6 jaar | |
Sigurd Kirk | M | 57 | 3 jaar | |
Rudy Howard | M | 67 | 2 jaar | |
Thomas Wellauer | M | 69 | - | |
Gary Sutton | M | - | 13 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 66 | 66.00% |
Zwitserland | 34 | 34.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- John Hohneker
- Persoonlijk netwerk